Phase II trial

Eye
#AMD #Aviceda Therapeutics #Geographic atrophy #Nanomedicine / nanotechnology #Ophthalmology #Phase II trial

Novel glycan-coated nanoparticle enters trials for geographic atrophy

Aviceda Therapeutics has dosed the first patient in its Phase II SIGLEC trial investigating AVD-104 as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a novel glycan-coated nanoparticle, supported by a strong pre-clinical in vivo efficacy and safety profile. Read More

#News

Neurons in the brain
#Algiax Pharmaceuticals #Neurology #Neuroscience #Painkillers #Phase II trial #Trial data

Phase IIa trial expanded for promising neuropathic pain drug

The independent Data Monitoring Committee (DMC) has recommended the continuation of Algiax Pharmaceuticals’ Phase IIa study with lead candidate AP-325 in chronic neuropathic pain. Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France,… Read More

#News

#Alzheimer's #Antibody #Eisai #MHRA #Neurodegenerative disorders #Phase II trial

Eisai applies for MHRA approval for lecanemab in Alzheimer’s

Eisai has submitted a marketing authorisation application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. The MAA is for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia)… Read More

#News #Regulatory

Lipid nanoparticle mRNA vaccine
#Advanced Therapies #Cell and gene therapy #Moderna #mRNA #Phase II trial #Rare disease

Positive initial data on first mRNA therapy for propionic acidemia

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The ongoing global Phase… Read More

#News #Trending News

Lungs
#Idiopathic pulmonary fibrosis #Lung disease #Phase II trial #Vicore Pharma

New drug shows sustained disease stabilisation in IPF

New Phase IIa data indicates that Vicore Pharma’s C21 has the potential to transform the treatment of idiopathic pulmonary fibrosis (IPF) and restore lung function. In data from the AIR trial, C21 has demonstrated long-term efficacy. At 36 weeks, the average forced vital capacity (FVC) had… Read More

#News

Institute of Cancer Research
#Algok Bio #Cancer research #Oncology #Phase II trial #The Institute of Cancer Research

Ovarian cancer drug enters Phase II trials

An ovarian cancer drug, which targets the alpha folate receptor (FRα), is set to enter Phase II trials. Idetrexed (formerly known as BTG945, ONX-0901 and CT900) was created by scientific teams in what is now The Institute of Cancer Research (ICR) Centre for Cancer Drug Discovery,… Read More

#Cancer Research #News

Two scientists working in a research laboratory
#BioGenCell #Clinical trial #Collaboration #Diabetes #Partnership #Phase II trial #University of California San Francisco

Industry-academia alliance targets chronic limb-threatening ischaemia

BioGenCell has partnered with the University of California San Francisco (UCSF) as part of the company’s Phase II clinical trials. The partnership will focus on the impact of BioGenCell’s treatment on those with chronic limb-threatening ischaemia (CLTI also known as CLI), a debilitating condition commonly associated… Read More

#News

Covid-19
#Axcella Therapeutics #Covid-19 #Long Covid #Mitochondria #Phase II trial #University of Oxford

Encouraging trial results for long Covid fatigue treatment

Researchers from the University of Oxford have reported findings from a Phase II clinical trial investigating the efficacy of an investigational treatment against long Covid fatigue. The study found that participants given the treatment, AXA1125, developed by US pharmaceutical company Axcella Therapeutics, felt less fatigued than… Read More

#Editor's Choice #News

#Cancer research #Clinical research #Clinical trial #Drug discovery #Oncology #Phase I trial #Phase II trial

Podcast shares industry highlights for 3-7 April

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headlines this week have revealed a high level of clinical trial activity taking place… Read More

#News

Ophthalmologist looks at retinal scan
#Artificial intelligence (AI) #Endogena Therapeutics #Ophthalmology #Phase I trial #Phase II trial #Retinitis pigmentosa

Retinitis pigmentosa drug proved safe in Phase I/IIa study

Endogena Therapeutics has completed the dose-escalation stage of its Phase I/IIa study of EA-2353 in retinitis pigmentosa (RP) with no clinically relevant or dose-limiting adverse events. Given the positive safety and tolerability profile, the study will now enrol patients into the expansion cohort, using the highest… Read More

#News

Woman with alcohol use disorder
#Beckley Psytech #Phase II trial #Psychedelics #Substance use disorders #Synthetic biology

Phase IIa study will investigate psychedelic for alcohol use disorder

Beckley Psytech has initiated a Phase IIa study investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD). BPL-003 is Beckley Psytech’s novel synthetic formulation of the psychedelic compound 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery… Read More

#News

#Cancer research #Clinical research #Clinical trial #Drug discovery #Oncology #Phase I trial #Phase II trial

This week in drug discovery (3-7 April)

News round-up for 3-7 April by DDW Digital Content Editor Diana Spencer.  The headlines this week have revealed a high level of clinical trial activity taking place internationally. In just the last few days, new clinical trials in colorectal cancer, osteoarthritis, and brain cancer have been launched,… Read More

#News

Colon cancer
#Cancer research #Cardiff Oncology #Clinical trial #Colorectal cancer #Oncology #Phase II trial

Metastatic colorectal cancer trial launches in the US

A Phase II trial to investigate onvansertib for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) has treated its first patients. The ONSEMBLE trial is designed to demonstrate a clinically meaningful difference in response and onvansertib’s contribution to standard of care (SoC)… Read More

#Cancer Research #News

#Chemotherapy #EpicentRx #FDA #Head and neck cancer #Oncology #Phase II trial

US FDA fast-tracks drug to prevent severe chemotherapy side effect

The US Food and Drug Administration (FDA) has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head and neck cancer patients. The FDA also accepted the company's Investigational New Drug (IND) application to initiate a follow-on Phase IIb clinical trial, called… Read More

#News #Regulatory

Idiopathic intracranial hypertension
#Brain #Neuroinflammation #Neurology #Phase II trial #Type 2 diabetes #University of Birmingham

Type 2 diabetes drug could treat blinding IIH headaches

Patients with ‘blinding’ headaches known as idiopathic intracranial hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study was led by a team of neurologists from the University of Birmingham and University Hospitals Birmingham, and… Read More

#News #Trending News

Atrial fibrillation
#Acesion Pharma #Cardiovascular disease #Clinical trial #Drug discovery #Phase II trial

Success for first new approach to atrial fibrillation for 20 years

The primary endpoint has been achieved in a Phase II trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of atrial fibrillation (AF) to normal sinus rhythm. Acesion Pharma enrolled 63 patients with a current episode of AF in the trial and tested two… Read More

#News